FDA Approves Thermo Fisher Scientific CDx for Genentech's Gavreto in NSCLC Patients With RET Fusions

NEW YORK – Thermo Fisher Scientific said on Tuesday that the US Food and Drug Administration has granted premarket approval for its Oncomine Dx Target Test as a companion diagnostic for pralsetinib (Gavreto), a targeted drug developed by Blueprint Medicines, to identify RET fusions in metastatic non-small cell lung cancer patients.